trending Market Intelligence /marketintelligence/en/news-insights/trending/bkbz9-o7ysyyz3wq9yaf0q2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Vanda Pharmaceuticals, Apotex settle patent litigation over schizophrenia drug

Independent Networks Gain Little Traction On Virtual Multichannel Services

Big Strategy Decisions Ahead For Viacom As It Moves Into The CBS Fold

Street Talk Episode 48 - Bank M&A, Investing Against An Inverted Yield Curve Overview

Asia OTT Leaders Continue To Expand Partnerships With Telcos


Vanda Pharmaceuticals, Apotex settle patent litigation over schizophrenia drug

Vanda Pharmaceuticals said it granted Apotex Inc. and Apotex Corp. a nonexclusive license to manufacture and sell a version of Fanapt in the U.S., effective Nov. 2, 2027.

The license agreement resolves Vanda's patent litigation against Apotex regarding the latter's abbreviated new drug application for its generic version of Vanda's Fanapt.

If Vanda obtains pediatric exclusivity for Fanapt before Nov. 2, 2027, the license, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, will be effective May 2, 2028.

Fanapt is used in the treatment of schizophrenia in adults.